Another promising delivery strategy for TLR7/8 agonists is throughtheir conjugation to tumor-targeting antibodies such as trastuzumab,which binds HER2.61 While preclinical datais quite promising, major limitations exist, such as downregulationof tumor-specific targeting antigens62,63 and inductionof antidrug antibodies,64 limiting theirlong-term clinical potential. The gene discussed is ERBB2; the disease is neoplasm.